Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41577-020-00421-x http://scihub22266oqcxt.onion/10.1038/s41577-020-00421-x 32778829!7416654!32778829     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nat+Rev+Immunol 2020 ; 20 (10): 587-588 Nephropedia Template TP {{tp|p=32778829|t=2020. After 62 years of regulating immunity, dexamethasone meets COVID-19 |pdf=|usr=}}{{32778829}} gab.com Text After 62 years of regulating immunity, dexamethasone meets COVID-19 JO: Nat Rev Immunol http://www.kidney.de/pget.php?&tw=1&pmid=32778829 #FOAvip Six months into the COVID-19 pandemic, effective treatments have been frustratingly sparse. The RECOVERY clinical trial, however, revealed that treatment with dexamethasone, a classic synthetic glucocorticoid, enhanced survival of critically ill patients with COVID-19. In this Comment, we discuss the immunological impacts of glucocorticoid therapy for COVID-19. Twit Text FOAVip After 62 years of regulating immunity, dexamethasone meets COVID-19 ????Nat Rev Immunol http://www.kidney.de/pget.php?&tw=1&pmid=32778829 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32778829 #FOAvip English Wikipedia <ref>{{Cite pmid|32778829}}</ref> After 62 years of regulating immunity, dexamethasone meets COVID-19 #MMPMID32778829 Cain DW; Cidlowski JA Nat Rev Immunol 2020[Oct]; 20 (10): 587-588 PMID32778829show ga Six months into the COVID-19 pandemic, effective treatments have been frustratingly sparse. The RECOVERY clinical trial, however, revealed that treatment with dexamethasone, a classic synthetic glucocorticoid, enhanced survival of critically ill patients with COVID-19. In this Comment, we discuss the immunological impacts of glucocorticoid therapy for COVID-19. |Alarmins/antagonists & inhibitors/genetics/immunology[MESH] |Anti-Inflammatory Agents/*therapeutic use[MESH] |Betacoronavirus/immunology/*pathogenicity[MESH] |COVID-19[MESH] |Coronavirus Infections/*drug therapy/immunology/pathology/virology[MESH] |Cytokine Release Syndrome/immunology/pathology/*prevention & control/virology[MESH] |Dexamethasone/*therapeutic use[MESH] |Drug Administration Schedule[MESH] |Humans[MESH] |Immunity, Innate/drug effects[MESH] |Immunosuppressive Agents/*therapeutic use[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy/immunology/pathology/virology[MESH] |Randomized Controlled Trials as Topic[MESH] |Receptors, Glucocorticoid/antagonists & inhibitors/genetics/immunology[MESH] |SARS-CoV-2[MESH] |Severity of Illness Index[MESH]After 62 years of regulating immunity, dexamethasone meets COVID-19 (epmc).pdf DeepDyve Pubget Overpricing